generic competition dented sales of five key medicines and the end of the pandemic wiped out demand for swine flu vaccines. Earnings slid to 2.17 billion euros ($3.23 billion), or 1.66 euros a share, excluding costs such as writedowns and merger...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Sanofi Profit Drops on Generics, Pandemic Flu End
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account
account